Bicara Therapeutics Inc. Common Stock 2026 Q2 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- Bicara Therapeutics reported strong execution in Q2 2026, advancing the pivotal phase 3 Fortify HNO1 study of FY Sara in frontline recurrent and metastatic HPV negative head and neck squamous cell cancer.
- At ASCO 2026, Bicara presented three-year follow-up data showing that TGF beta inhibition with FY Sara nearly doubled overall survival versus standard of care while maintaining a consistent safety profile.
- Total operating expenses increased in Q2 2026 compared to Q2 2025, driven by clinical operations, development expenses, manufacturing costs, and personnel-related costs including stock-based compensation.
- Bicara ended Q2 2026 with approximately $497 million in cash, cash equivalents, and marketable securities, providing runway into the first half of 2029.
- Enrollment in the Fortify HNO1 study is on track for substantial completion by year-end 2026, positioning the company for an interim analysis in mid-2027 and potential accelerated approval.
- The company initiated the 4 to 5 Flex alternative dosing study to support a loading and every three-week maintenance dose, aiming to have data in hand by potential U.S. approval.
- Bicara is expanding development beyond head and neck cancer, with proof of concept established in cutaneous squamous cell carcinoma and anal canal cancer, and ongoing signal-seeking studies in colorectal cancer.
- Leadership transitions were announced: Ryan Kohlhepp will become CEO in early 2027, Claire Mazumdar will transition to Vice Chair and Strategic Advisor, Jen Larson will become CFO effective immediately, Tanya Green will become COO, Jenna Cohen will become Chief Business Officer, and Greg Shiffman will join as Chief Legal Officer.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good day, and thank you for standing by. Welcome to the Bicara Therapeutics second quarter 2026 earnings conference call. At this time, all participants are in listen only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star one one again. Please be advised that today's conference is being recorded. I would now like to turn the conference over to your speaker for today, Rachel Frank.
Please go ahead. Thank you, and good morning, everyone.
It is a pleasure to welcome you to Bicara Therapeutics second quarter 2026 earnings call. Earlier this morning, we issued a press release highlighting results from the quarter and provided a business update, including strategic leadership transitions, marking the company's next era of growth and execution. You can access the press release as well as the slides that we will be reviewing today by going to the investor section of our company website. Before we begin, please note that this call will include forward-looking statements under the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Please refer to our most recent SEC filings for important risk factors that could cause our actual performance and results to materially differ from those expressed or implied in these forward-looking statements.
Any forward-looking statement made on this call represents our views only as of today, and we disclaim any obligation to update any forward-looking statements. Joining us on the call today are Claire Mazumdar, Chief Executive Officer, Ryan Cohlhepp, President and Chief Operating Officer, and Ivan Hyep, Chief Financial Officer. I will now turn the call over to Claire.
Before we get into today's announcements, I want to begin by acknowledging what has been another important quarter for Bicara. Across the organization, our team has continued to execute with focus and discipline as we advance the pivotal phase III FORTIFI-HN01 study of ficerafusp alfa, or FICERA, in frontline recurrent and metastatic HPV-negative head and neck squamous cell cancer. We also have strengthened our operational capabilities as we prepare the company for an exciting next chapter as we near a top-line interim analysis of our pivotal study and potential commercialization. Part of that momentum was our ASCO 2026 update, where we presented three-year follow-up data showing that TGF-β inhibition leading to direct tumor penetration translates to unprecedented depth and duration of response. At three years, FICERA nearly doubled overall survival versus standard of care while maintaining a consistent safety profile, all driven by TGF-β inhibition.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
15 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring